In situ cell cycle analysis in giant cell tumor of bone reveals patients with elevated risk of reduced progression-free survival

Bone ◽  
2019 ◽  
Vol 127 ◽  
pp. 188-198 ◽  
Author(s):  
Mate E. Maros ◽  
Sven Schnaidt ◽  
Peter Balla ◽  
Zoltan Kelemen ◽  
Zoltan Sapi ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Progression Free Survival ◽  
Elevated Risk ◽  
Cell Tumor ◽  
Cell Cycle Analysis ◽  
Free Survival

scholarly journals Similar outcomes with first-line observation versus metastasectomy for bone giant cell tumor lung metastases

2020 ◽  
Author(s):  
Shinji Tsukamoto ◽  
Giovanni Ciani ◽  
Andreas F. Mavrogenis ◽  
Cristina Ferrari ◽  
Manabu Akahane ◽  
...  
Keyword(s):  
Disease Progression ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Lung Metastases ◽  
Progression Free Survival ◽  
Cell Tumor ◽  
First Line ◽  
Free Survival ◽  
Line Management

Abstract Background: The outcome of lung metastases in patients with giant cell tumor of bone (GCTB) varies from spontaneous regression to uncontrolled growth. To investigate whether observation is an appropriate first-line management for patients with lung metastases from GCTB, we compared the outcomes of patients initially treated with observation with those treated with metastasectomy.Methods: We retrospectively reviewed the data of 29 patients with lung metastases from histologically confirmed GCTB. The median follow-up period was 114 months. We evaluated progression-free survival, which was defined as the time from the date of occurrence of lung metastases to the date of disease progression in the observation or incomplete metastasectomy group, disease recurrence in the complete metastasectomy group, or the last follow-up.Results: Disease progression or recurrence occurred in 14 patients (48.3%). Progression-free survival did not vary significantly between the observation and metastasectomy groups (p=0.373). The number of metastasectomies was significantly higher in the initial metastasectomy group than in the observation group (p=0.017).Conclusions: Observation can be used safely as first-line management for patients with lung metastases from GCTB with an outcome similar to that of metastasectomy.

scholarly journals Similar outcomes with first-line observation versus metastasectomy for bone giant cell tumor lung metastases

2020 ◽  
Author(s):  
Shinji Tsukamoto ◽  
Giovanni Ciani ◽  
Andreas F. Mavrogenis ◽  
Cristina Ferrari ◽  
Manabu Akahane ◽  
...  
Keyword(s):  
Disease Progression ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Lung Metastases ◽  
Progression Free Survival ◽  
Cell Tumor ◽  
First Line ◽  
Free Survival ◽  
Number Of Patients

Abstract Background: The outcome of lung metastases in patients with giant cell tumor of bone (GCTB) varies from spontaneous regression to uncontrolled growth. To investigate whether observation is an appropriate first-line management for patients with lung metastases from GCTB, we compared the outcomes of patients initially treated with observation with those treated with metastasectomy.Methods: We retrospectively reviewed the data of 29 patients with lung metastases from histologically confirmed GCTB. The median follow-up period was 114 months. We evaluated progression-free survival, which was defined as the time from the date of occurrence of lung metastases to the date of disease progression in the observation or incomplete metastasectomy group, disease recurrence in the complete metastasectomy group, or the last follow-up.Results: Disease progression or recurrence occurred in 14 patients (48.3%). Progression-free survival did not vary significantly between the observation and metastasectomy groups (p=0.373). The total number of metastasectomies was significantly higher in the initial metastasectomy group than in the observation group (p=0.017).Conclusions: The number of patients included in this study is small, however the data suggests that observation can be used safely as first-line management for patients with lung metastases from GCTB with an outcome similar to that of metastasectomy. It is necessary to confirm our result in multi-institutional study with sufficient number of patients.

scholarly journals p63 regulates cell proliferation and cell cycle progression-associated genes in stromal cells of giant cell tumor of the bone

2012 ◽  
Vol 42 (2) ◽  
pp. 437-443 ◽  
Author(s):  
CAROL PO YING LAU ◽  
PATRICK KWOK SHING NG ◽  
MAN SHAN LI ◽  
STEPHEN KWOK WING TSUI ◽  
LIN HUANG ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Cell Proliferation ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Stromal Cells ◽  
Cell Cycle Progression ◽  
Cell Tumor ◽  
Cycle Progression

scholarly journals Cell Cycle Regulatory Protein Expression in Multinucleated Giant Cells of Giant Cell Tumor of Bone: do They Proliferate?

2021 ◽  
Vol 27 ◽  
Author(s):  
Mate E. Maros ◽  
Peter Balla ◽  
Tamas Micsik ◽  
Zoltan Sapi ◽  
Miklos Szendroi ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Regulatory Protein ◽  
Giant Cells ◽  
Cell Tumor ◽  
G1 Phase ◽  
Cdk Inhibitors ◽  
Multinucleated Giant Cells ◽  
Early Replication

Cells of the monocyte macrophage lineage form multinucleated giant cells (GCs) by fusion, which may express some cell cycle markers. By using a comprehensive marker set, here we looked for potential replication activities in GCs, and investigated whether these have diagnostic or clinical relevance in giant cell tumor of bone (GCTB). GC rich regions of 10 primary and 10 first recurrence GCTB cases were tested using immunohistochemistry in tissue microarrays. The nuclear positivity rate of the general proliferation marker, replication licensing, G1/S-phase, S/G2/M-phase, mitosis promoter, and cyclin dependent kinase (CDK) inhibitor reactions was analyzed in GCs. Concerning Ki67, moderate SP6 reaction was seen in many GC nuclei, while B56 and Mib1 positivity was rare, but the latter could be linked to more aggressive (p = 0.012) phenotype. Regular MCM6 reaction, as opposed to uncommon MCM2, suggested an initial DNA unwinding. Early replication course in GCs was also supported by widely detecting CDK4 and cyclin E, for the first time, and confirming cyclin D1 upregulation. However, post-G1-phase markers CDK2, cyclin A, geminin, topoisomerase-2a, aurora kinase A, and phospho-histone H3 were rare or missing. These were likely silenced by upregulated CDK inhibitors p15INK4b, p16INK4a, p27KIP1, p53 through its effector p21WAF1 and possibly cyclin G1, consistent with the prevention of DNA replication. In conclusion, the upregulation of known and several novel cell cycle progression markers detected here clearly verify early replication activities in GCs, which are controlled by cell cycle arresting CDK inhibitors at G1 phase, and support the functional maturation of GCs in GCTB.

Bilateral Mirror-Symmetrical Giant Cell Tumor of the Tendon Sheath in the Foot and Ankle: A Case Report

2021 ◽  
Vol 60 (1) ◽  
pp. 163-166
Author(s):  
Naji S. Madi ◽  
Said Saghieh ◽  
Ahmad Salah Naja ◽  
Rachid K. Haidar
Keyword(s):  
Case Report ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Tendon Sheath ◽  
Cell Tumor ◽  
Foot And Ankle
Sign in / Sign up

Export Citation Format

Share Document